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Abstracts / Osteoarthritis and Cartilage 22 (2014) S7–S56S8controls. Furthermore, there was no signiﬁcant correlation between the
paired serum and synovial ﬂuid levels at baseline (Spearman R<0.2 for
all markers). The positive predictive value of a raised serum level of IL-6
or TSG-6 for an elevated synovial ﬂuid level respectively were 80% and
89%, but with negative predictive values of 49% and 20%. At 3 months
from baseline, analytes generally remained low in blood, and had also
normalised in synovial ﬂuid, where the latter was available. Exceptions
were MMP-3 and TSG-6, where elevated levels persisted in the serum
and synovial ﬂuid in a proportion of individuals at this later time.
Conclusions: Our ﬁndings validate the utility of the murine post-
traumatic OA model in identifying potential human joint injury
response biomarkers. In this translational setting, analysis of synovial
ﬂuid rather than blood appears essential for the accurate assay of cel-
lular products secreted into the joint in response to injury. Neither
serum nor plasma levels are clinically sensitive enough to be surrogates
for the intra-articular response. Investigation of the pathogenetic
relevance and prognostic value of an individual’s initial molecular
response to joint injury in prospective cohorts such as KICK is essential
to our understanding of post-traumatic OA.
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Purpose: Osteoarthritis (OA) is the most common joint disease. Among
the earliest lesions during OA development is disruption of the super-
ﬁcial zone (SZ) of articular cartilage. Our recent studies showed that the
chromatin protein high mobility group protein B2 (HMGB2) is uniquely
expressed in the SZ and its expression declines with aging in human
and mouse joints. Deletion of the hmgb2 gene leads to increased
severity of aging-related OA. HMGB2 supports SZ cell survival through
interactions with Wnt signaling and maintains the immature differ-
entiation status of these cells. To further elucidate HMGB2 functions we
performed gene expression analyses and identiﬁed EFEMP1 encoding
ﬁbulin-3 as a HMGB2 regulated gene. Fibulin-3 is one of sevenmembers
of the mammalian ﬁbulin family of glycoproteins. Fibulin-3 is expressed
in cartilage and bone structures in the embryo and ﬁbulin-3 peptides
are potential biomarkers for the diagnosis of OA. However, the
expression pattern and function of ﬁbulin-3 in adult joint tissues is not
well characterized. The purposes of this study were to examine ﬁbulin-
3 expression patterns in joint aging and OA and to investigate the role of
ﬁbulin-3 in OA pathogenesis.
Methods: Human knee joints were obtained at autopsy with approval
of the Human Subjects Committee. Joints were processed within 72
hours post-mortem. All animal experiments were performed according
to protocols approved by the Institutional Animal Care and Use Com-
mittee. Immunohistochemical analysis was performed on human and
mouse knee cartilage to determine changes in ﬁbulin-3 expression
during joint aging and in OA. To examine the role of ﬁbulin-3 in carti-
lage homeostasis, aging-related OA and experimental OA (induced by
transection of the medial meniscotibial ligament and the medial col-
lateral ligament) were investigated in wild type and ﬁbulin-3-/- mice.
To address whether ﬁbulin-3 is involved in regulating chondrocyte
differentiation and cell viability, human articular chondrocytes were
transfected with ﬁbulin-3-speciﬁc siRNA. Cells were harvested at 48
hours and 72 hours for quantitative PCR and Western blot analyses.
Following transfection with siRNA and incubation for 72 hours, cell
viability was determined using MTT assay. To further address the role of
ﬁbulin-3 during chondrogenesis, bonemarrowmesenchymal stem cells
(MSC) were transduced with lentivirus (LV) encoding EFEMP1 or con-
trol LV expressing LacZ, then MSC pellets were prepared and analyzed
for chondrogenesis. Statistically signiﬁcant differences between two
groups were determined by Mann-Whitney’s U test (non-parametric)
or Student’s t-test (parametric). Differences among 3 groups were
determined by Kruskal-Wallis (non-parametric one-way analysis of
variance) or Tukey-Kramer (parametric) procedures. P values of less
than 0.05 were considered statistically signiﬁcant.
Results: Fibulin-3 was speciﬁcally expressed in the SZ of normal car-
tilage in human and mouse knee joints. Fibulin-3 expression was
intracellular and in the extracellular matrix (ECM) and declined with
aging. Both aging-related OA and experimental OA were signiﬁcantly
more severe in ﬁbulin-3-/- mice comparedwith wild typemice. Fibulin-3-/- mice showed signiﬁcantly fewer SZ cells compared with WT mice
in 9 months. There was a signiﬁcant reduction in chondrocyte viability
following ﬁbulin-3 knockdown under low serum conditions. Fibulin-3
expression was high in MSC and decreased during chondrogenesis.
Suppression of ﬁbulin-3 by siRNA in MSC signiﬁcantly increased SOX9,
collagen II and aggrecan in articular chondrocytes, while the over-
expression of ﬁbulin-3 inhibited chondrogenesis in MSC.
Conclusions: We found that ﬁbulin-3 is speciﬁcally expressed in the SZ
of articular cartilage and its expression is reduced in aging. Fibulin-3
regulates survival and differentiation of adult progenitor cells in the SZ
of articular cartilage and its aging-related decline is an early event in OA
pathogenesis. Preventing or restoring aging-associated loss of ﬁbulin-3
in SZ chondrocytes has potential to delay or prevent onset of OA.
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Purpose: The purpose of this study is to investigate the role of Wnt16
following cartilage injury and osteoarthritis development. Our previous
studies showed that Wnt16 is up-regulated upon acute trauma -a
condition known to predispose to osteoarthritis (OA) - in an ex vivo
setting. Activation of Wnt signalling is associated with cartilage
breakdown and OA development, although the mechanisms and the
ligands responsible for it are still unclear. The aims of this study,
therefore, are i) to investigate whether Wnt16 contributes to the out-
come of experimental OA in vivo; ii) The molecular mechanism leading
to WNT16 up-regulation following injury and iii) identify which sig-
nalling pathway is activated by Wnt16 in vivo.
Methods: Articular chondrocytes were isolated from bovine metatarsal
joints. The cells were then stimulated with recombinant Wnt16 at dif-
ferent doses and gene expression analysis performed. OA was induced
by destabilization of the medial meniscus (DMM) in 8 week-old 129/Sv
mice Wnt16-/- or WT littermate. The animals were culled at 2, 7 days
and 8 weeks post surgery. The joints were either processed for gene
expression analysis, ﬁxed for bone analysis (mCt) or de-calciﬁed and
parafﬁn embedded, for histological, morphometric, and immunohis-
tochemical characterization. The degree of cartilage breakdown was
assessed by using OARSI score by two independent investigators. Six
animals/genotype were left ageing for 1 year to evaluate the develop-
ment of spontaneous OA. To test the involvement to oxidative stress in
Wnt16 modulation, organ cultures of articular cartilage explanted from
femoral heads were treated with H2O2 in presence/absence of a NADPH
oxidase inhibitor. Gene expression analysis for Wnt16 and cartilage
markers performed afterwards.
Results: Wnt16 expression was upregulated at 2 and 7 days post-DMM
and was associated with an increased expression of b-catenin. Modu-
lation of the Wnt-bcatenin pathway was conﬁrmed in vitro on bovine
articular chondrocytes stimulated with recombinant Wnt16. Wnt16-
deﬁcient mice developed more severe cartilage breakdown in com-
parison toWT littermate following DMM, whereas, if left unchallenged,
did not develop spontaneous OA with age. Wnt16-deﬁcient mice dis-
played a lower expression of lubricin, the absence of which is known to
result in OA. Finally, we found that mechanical trauma to cartilage
resulted in oxygen radical release, and this was required and sufﬁcient
to trigger WNT16 upregulation in chondrocytes. Indeed H2O2 alone
was sufﬁcient to up-regulate WNT16, whereas chemical blockade of
NAPDH oxidase inhibited WNT16 up-regulation induced by mechanical
trauma.
Conclusions: We demonstrated for the ﬁrst time that Wnt16 supports
cartilage homeostasis following injury, and it is required to reduce
degradation upon mechanical trauma. We also showed that oxidative
stress, previously thought to play a pathogenic role in cartilage break-
down in the ﬁrst phases of OA development, in our settings, drives
Wnt16 up-regulation, suggesting a new homeostatic role for oxidative
stress. Finally, we show that Wnt16 supports the expression of lubricin.
Our results shed new light on the role of Wnt signalling in the articular
Abstracts / Osteoarthritis and Cartilage 22 (2014) S7–S56 S9cartilage and open a new window of opportunity to modulate the Wnt
pathway for the treatment of acute and chronic cartilage injury.
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Purpose: Most patients who have hip replacement do so to relieve pain
and stiffness associated with osteoarthritis. However, around 10% of
patients who have total hip replacement report chronic pain related to
their operated joint 3 months after surgery. It is important to identify
ways to reduce the chance that patients will have this type of ongoing
pain. A known risk factor for chronic post-surgical pain is the severity of
acute post-operative pain. There is evidence that local anaesthetic
wound inﬁltration reduces acute post-operative pain; however, it is
uncertain whether it is also effective at reducing chronic pain in the
long-term. The aim of this randomised controlled trial (RCT) was to
determine if local anaesthetic wound inﬁltration could signiﬁcantly
reduce the severity of joint pain at 12-months after total hip
replacement.
Methods: This study was a double-blind randomised controlled trial of
patients undergoing primary total hip replacement for osteoarthritis at
a high volume elective orthopaedic centre in the UK. Patients were
randomised to receive additional intra-operative local anaesthetic
wound inﬁltration or the standard anaesthesia regimen alone. The
usual anaesthesia regimen consisted of spinal or general anaesthetic,
depending on patient clinical factors. Patients in the intervention group
received an added injection of 60 mls of 0.25% bupivacaine with 1 in
200,000 adrenaline at the wound site before surgical closure. Post-
operative pain management was the same for the intervention and
usual care group, and included a patient-controlled analgesia device.
Randomisation was minimised by baseline hip pain severity and sur-
gical approach. The primary outcome was pain at 12-months post-
operative measured by the WOMAC Pain scale. Secondary outcomes
included the WOMAC Function and Stiffness scales, the Intermittent
and Constant Osteoarthritis Pain (ICOAP) measure and the PainDETECT
(a measure of neuropathic pain), collected by postal questionnaires
administered at 3-months, 6-months and 12-months after surgery.
Measurements of daily acute post-operative pain severity were col-
lected on post-operative days 1-3 using a visual analogue scale. Com-
plications and adverse events were collected from patients’ self-report
at 3-months and 12-months and a review of medical records. WOMAC
Pain scores at 12-months post-operative were categorised into “No
pain”; “Mild”; “Moderate” and “Severe” and analyzed using generalized
ordered logit models in an intent-to-treat approach. Results are pre-
sented as odds ratios and 95% conﬁdence intervals (CIs). Secondary
outcomes were analysed using generalised linear models and general-
ized linear mixed models.
Results: 639 eligible patients were approached to take part in this study
and 322 consented to participate (50% recruitment rate). Prior to sur-
gery, 163 patients were randomised to the intervention group and 159
to the standard care group. Patients receiving additional local anaes-
thetic wound inﬁltration were less likely to report severe pain at 12-
months post-operative compared with patients receiving the usual
anaesthetic regimen alone (OR¼0.13; 95% CIs¼0.03, 0.62; p¼0.011). At
12-months post-operative, patients in the intervention group were also
less likely to report neuropathic pain on the PainDETECT questionnaire
(OR¼0.22; 95% CIs¼0.05, 0.97; p¼0.046). No differences were observed
for outcomes assessed through ICOAP, WOMAC function or WOMAC
stiffness questionnaires. During their inpatient stay, patients of both
groups reported comparable levels of daily pain, with the exception of
pain on the second post-operative night (Coef.¼ -0.83; 95% CIs -1.41,
-0.26; p¼0.005). Complications and adverse events were similar
between the intervention and standard care groups.
Conclusions: This is the ﬁrst RCT to assess the longer-term effects of a
local anaesthetic wound inﬁltration on pain severity after hip replace-
ment. We found that local anaesthetic wound inﬁltration administered
before wound closure is effective in reducing the number of patients
experiencing severe pain at 12-months after hip replacement. There
was also some evidence of reductions in neuropathic pain at 12-monthspost-operative and pain on the second post-operative night for patients
in the intervention group compared with the usual care group. We
recommend the addition of local anaesthetic wound inﬁltration to the
usual anaesthesia regimen during primary total hip replacement sur-
gery to reduce the risk of severe chronic pain after surgery.
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Purpose: The main goal of this comparative study was to investigate
whether exercise therapy added to general practitioners’ care is effec-
tive compared to general practitioners’ care only in patients with a new
episode of hip OA in general practice, over a period of 12 months.
Methods: Study design used was a randomized controlled trial with a
parallel group design. Patients could participate the trial if they were 45
years or older, comply with the clinical American College of Rheuma-
tology criteria for hip OA, and visited their general practitioner for a new
episode of complaints due to hip osteoarthritis. Patients were excluded
if they: 1) were already treated with exercise therapy in the present
episode of hip OA, 2) had a hip pain score of<2 on the 11-point numeric
rating scale (0 to 10), 3) had a high level of physical function, a score of
<2 on the walking ability and the physical function sections of the
Algofunctional index, 4) had undergone hip surgery or those on the
waiting list for surgery, 5) had severe disabling co-morbidity and 6) had
insufﬁcient comprehension of the Dutch language and/or were men-
tally incapable of participation. The patients were randomized using
sealed envelopes based on a computer generated random table in two
treatment groups: one group received exercise therapy supervised by a
physiotherapist added to general practitioners’ care and the control
group received general practitioners’ care only. The exercise therapy
consisted of up to 15 sessions in the ﬁrst threemonths and three follow-
up (booster)sessions in month ﬁve, seven and nine. The primary out-
comesmeasured for the clinical studywere severity of hip pain and hip-
related function measured with the Hip disability Osteoarthritis Out-
come Score (HOOS). Secondary outcome measures were: severity of hip
pain averaged over past week measured with an 11-point numerical
rating scale, severity of intermittent and constant hip pain measured
with the Intermittent and Constant Osteoarthritis Pain (ICOAP) ques-
tionnaire, functional mobility measure with the timed Up and Go test,
patients’ perceived recovery measured with a 7-point Likert scale,
quality of life measuredwith the EQ-5D instrument. The patients scored
the outcomes using questionnaires at 6 weeks and at 3, 6, 9 and 12
months after baseline measurement. All analyses were performed
according to intention to treat principle. We used linear mixed models
analysis with repeated measurements and adjusted the analysis for age
and body mass index.
Results: The study took place in the period 2009-2012 and 203 patients
from 101 general practitioners participated. The mean age was 65 years
and there were slightly more women (60%) than men. Randomly allo-
cated to the exercise group were 101 patients and 102 patients to the
group that received general practitioners’ care only. At baseline both
groups were quite similar, however, the number of patients who
reported performing unsupervised hip exercises prior to baseline was
15% higher in the control group. In addition, the number of patients
reporting using pain medication daily prior to baseline was 10% higher
in the control group. Therefore, besides age and body mass index,
analyses were also adjusted for these two variables. Regarding com-
pliance: 97 (96%) of the patients in the exercise group had visited a
physiotherapist. Mean number of visits was 9 (SD 4.0). Forty-eight
patients (48%) had 1 booster session, 46 (46%) 2 booster sessions and 36
(36%) received all three prescribed booster sessions. In the control
group, 14 (14%) patients had visited a physiotherapist (mean visits: 8;
SD 6.2). At 3 months follow-up there were statistically signiﬁcant and
clinically relevant differences between the groups on the primary
outcomes HOOS pain -3.9 (95%CI -7.7;-0.1: p-value of 0.04) and HOOS
function -5.2 (95%CI -9.1;-1.2: p-value of 0.01) in favor of the patients
who received the exercise therapy. However, this effect was no longer
present after 12 months follow-up. The analyses showed the same for
